In vivo evaluation of the effectiveness of two antiseptic solutions in reducing the viral load of SARS-CoV-2 in the saliva of patients with COVID-19

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

REBEC

Registry ID

RBR-10hj7jyn

Enrollment

Unknown

Registered

2021-02-04

Start date

2021-01-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus infection of unspecified location

Interventions

Experimental Group 1: 12 individuals, with symptoms of COVID-19 and who had already tested positive for SARS-CoV-2 using nasopharyngeal swabs, they will receive a mouthwash containing: A- chlorhexidin

VS2.003.002.005.003

Eligibility

Inclusion criteria

Inclusion criteria: Volunteers with symptoms of COVID-19; both genders; no age limit; no weight limit

Exclusion criteria

Exclusion criteria: Patients with cognitive impairment

Design outcomes

Primary

Measure	Time frame
Qualitative and quantitative analysis of the presence of SARS coronavirus-2 in the saliva of individuals before and after rinsing with mouthwash	—

Secondary

Measure	Time frame
Secondary outcomes are not expected.	—

Countries

Brazil

Contacts

Public ContactTaísa Guimarães

taisa-coelho@uol.com.br+552198389-8182

Outcome results

None listed

Source: REBEC (via WHO ICTRP)